Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Higher levels of SDMA and not ADMA are associated with poorer survival of trial patients with systemic ANCA-associated vasculitis.

Erdbrügger U, Kielstein JT, Westman K, Ma JZ, Xin W, Bode-Böger SM, Segelmark M, Rasmussen N, De Groot K.

Eur J Rheumatol. 2018 Apr 2:1-6. doi: 10.5152/eurjrheum.2018.17119. [Epub ahead of print]

PMID:
30071927
2.

Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis.

Weiner M, Bjørneklett R, Hrušková Z, Mackinnon B, Poulton CJ, Sindelar L, Mohammad AJ, Eriksson P, Gesualdo L, Geetha D, Crnogorac M, Jayne D, Hogan SL, Geddes C, Tesar V, Aasarød K, Segelmark M.

Nephrol Dial Transplant. 2018 Apr 30. doi: 10.1093/ndt/gfy106. [Epub ahead of print]

PMID:
29718465
3.

Routinely used immunoassays do not detect circulating anti-GBM antibodies against native NC1 hexamer and EA epitope of the α3 chain of type IV collagen.

Clavarino G, Gauthier A, Hellmark T, Carron PL, Giovannini D, Colliard S, Dragon-Durey MA, Segelmark M, Cesbron JY, Dumestre-Pérard C.

Eur J Immunol. 2018 Jun;48(6):1082-1084. doi: 10.1002/eji.201747324. Epub 2018 May 2.

PMID:
29644627
4.

The European Vasculitis Society 2016 Meeting Report.

Bajema IM, Bruijn JA, Casian A, Cid MC, Csernok E, van Daalen E, Harper L, Hauser T, Little MA, Luqmani RA, Mahr A, Ponte C, Salama A, Segelmark M, Suzuki K, Sznajd J, Teng YKO, Vaglio A, Westman K, Jayne D.

Kidney Int Rep. 2017 Sep 21;2(6):1018-1031. doi: 10.1016/j.ekir.2017.09.008. eCollection 2017 Nov.

5.

Frequency, Diagnosis, Treatment, and Outcome of Gastrointestinal Disease in Granulomatosis with Polyangiitis and Microscopic Polyangiitis.

Eriksson P, Segelmark M, Hallböök O.

J Rheumatol. 2018 Apr;45(4):529-537. doi: 10.3899/jrheum.170249. Epub 2018 Feb 1.

PMID:
29419474
6.

Epidemiology of primary systemic vasculitis in children: a population-based study from southern Sweden.

Mossberg M, Segelmark M, Kahn R, Englund M, Mohammad AJ.

Scand J Rheumatol. 2018 Jul;47(4):295-302. doi: 10.1080/03009742.2017.1412497. Epub 2018 Feb 7. Erratum in: Scand J Rheumatol. 2018 Jul;47(4):344.

PMID:
29409373
7.

Lymphocytes eject interferogenic mitochondrial DNA webs in response to CpG and non-CpG oligodeoxynucleotides of class C.

Ingelsson B, Söderberg D, Strid T, Söderberg A, Bergh AC, Loitto V, Lotfi K, Segelmark M, Spyrou G, Rosén A.

Proc Natl Acad Sci U S A. 2018 Jan 16;115(3):E478-E487. doi: 10.1073/pnas.1711950115. Epub 2018 Jan 2.

8.

Increased platelet activation occurs in cystic fibrosis patients and correlates to clinical status.

Lindberg U, Svensson L, Hellmark T, Segelmark M, Shannon O.

Thromb Res. 2018 Feb;162:32-37. doi: 10.1016/j.thromres.2017.12.012. Epub 2017 Dec 19.

PMID:
29274562
9.

Brief Report: Rituximab for the Treatment of Adult-Onset IgA Vasculitis (Henoch-Schönlein).

Maritati F, Fenoglio R, Pillebout E, Emmi G, Urban ML, Rocco R, Nicastro M, Incerti M, Goldoni M, Trivioli G, Silvestri E, Mohammad AJ, Jayne D, Eriksson P, Segelmark M, Novikov P, Harris H, Roccatello D, Vaglio A.

Arthritis Rheumatol. 2018 Jan;70(1):109-114. doi: 10.1002/art.40339. Epub 2017 Dec 1.

PMID:
28973844
10.

Neutrophil extracellular traps in vasculitis, friend or foe?

Söderberg D, Segelmark M.

Curr Opin Rheumatol. 2018 Jan;30(1):16-23. doi: 10.1097/BOR.0000000000000450. Review.

PMID:
28957962
11.

Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts.

Yates M, Watts R, Bajema I, Cid M, Crestani B, Hauser T, Hellmich B, Holle J, Laudien M, Little MA, Luqmani RA, Mahr A, Merkel P, Mills J, Mooney J, Segelmark M, Tesar V, Westman KWA, Vaglio A, Yalçındağ N, Jayne DR, Mukhtyar C.

RMD Open. 2017 Jun 15;3(1):e000449. doi: 10.1136/rmdopen-2017-000449. eCollection 2017.

12.

Severe Infection in Antineutrophil Cytoplasmic Antibody-associated Vasculitis.

Mohammad AJ, Segelmark M, Smith R, Englund M, Nilsson JÅ, Westman K, Merkel PA, Jayne DRW.

J Rheumatol. 2017 Oct;44(10):1468-1475. doi: 10.3899/jrheum.160909. Epub 2017 Aug 1.

PMID:
28765251
13.

Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.

Karras A, Pagnoux C, Haubitz M, Groot K, Puechal X, Tervaert JWC, Segelmark M, Guillevin L, Jayne D; European Vasculitis Society.

Ann Rheum Dis. 2017 Oct;76(10):1662-1668. doi: 10.1136/annrheumdis-2017-211123. Epub 2017 May 25.

PMID:
28546260
14.

Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients.

McAdoo SP, Tanna A, Hrušková Z, Holm L, Weiner M, Arulkumaran N, Kang A, Satrapová V, Levy J, Ohlsson S, Tesar V, Segelmark M, Pusey CD.

Kidney Int. 2017 Sep;92(3):693-702. doi: 10.1016/j.kint.2017.03.014. Epub 2017 May 12.

15.

Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.

Jayne DRW, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton P, Burst V, Grundmann F, Jadoul M, Szombati I, Tesař V, Segelmark M, Potarca A, Schall TJ, Bekker P; CLEAR Study Group.

J Am Soc Nephrol. 2017 Sep;28(9):2756-2767. doi: 10.1681/ASN.2016111179. Epub 2017 Apr 11.

PMID:
28400446
16.

C1-Inhibitor Decreases the Release of Vasculitis-Like Chemotactic Endothelial Microvesicles.

Mossberg M, Ståhl AL, Kahn R, Kristoffersson AC, Tati R, Heijl C, Segelmark M, Leeb-Lundberg LMF, Karpman D.

J Am Soc Nephrol. 2017 Aug;28(8):2472-2481. doi: 10.1681/ASN.2016060637. Epub 2017 Mar 13.

17.

Microvesicle transfer of kinin B1-receptors is a novel inflammatory mechanism in vasculitis.

Kahn R, Mossberg M, Ståhl AL, Johansson K, Lopatko Lindman I, Heijl C, Segelmark M, Mörgelin M, Leeb-Lundberg LM, Karpman D.

Kidney Int. 2017 Jan;91(1):96-105. doi: 10.1016/j.kint.2016.09.023. Epub 2016 Dec 1.

PMID:
27914700
18.

The clinical presentation and therapy of diseases related to anti-neutrophil cytoplasmic antibodies (ANCA).

Weiner M, Segelmark M.

Autoimmun Rev. 2016 Oct;15(10):978-82. doi: 10.1016/j.autrev.2016.07.016. Epub 2016 Jul 29. Review.

19.

Neutrophil Extracellular Traps in ANCA-Associated Vasculitis.

Söderberg D, Segelmark M.

Front Immunol. 2016 Jun 30;7:256. doi: 10.3389/fimmu.2016.00256. eCollection 2016. Review.

20.

Home- or Institutional Hemodialysis? - a Matched Pair-Cohort Study Comparing Survival and Some Modifiable Factors Related to Survival.

Rydell H, Clyne N, Segelmark M.

Kidney Blood Press Res. 2016;41(4):392-401. doi: 10.1159/000443441. Epub 2016 Jun 27.

21.

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.

Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, Hellmich B, Holle JU, Laudien M, Little MA, Luqmani RA, Mahr A, Merkel PA, Mills J, Mooney J, Segelmark M, Tesar V, Westman K, Vaglio A, Yalçındağ N, Jayne DR, Mukhtyar C.

Ann Rheum Dis. 2016 Sep;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133. Epub 2016 Jun 23.

22.

Comorbidities in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis versus the General Population.

Englund M, Merkel PA, Tomasson G, Segelmark M, Mohammad AJ.

J Rheumatol. 2016 Aug;43(8):1553-8. doi: 10.3899/jrheum.151151. Epub 2016 Jun 1.

PMID:
27252425
23.

IgA- and SIgA anti-PR3 antibodies in serum versus organ involvement and disease activity in PR3-ANCA-associated vasculitis.

Sandin C, Eriksson P, Segelmark M, Skogh T, Kastbom A.

Clin Exp Immunol. 2016 May;184(2):208-15. doi: 10.1111/cei.12769. Epub 2016 Feb 25.

24.

Long-term Kidney Transplant Outcomes in Primary Glomerulonephritis: Analysis From the ERA-EDTA Registry.

Pippias M, Stel VS, Aresté-Fosalba N, Couchoud C, Fernandez-Fresnedo G, Finne P, Heaf JG, Hoitsma A, De Meester J, Pálsson R, Ravani P, Segelmark M, Traynor JP, Reisæter AV, Caskey FJ, Jager KJ.

Transplantation. 2016 Sep;100(9):1955-62. doi: 10.1097/TP.0000000000000962.

PMID:
26588008
25.

Glomerular filtration rate (GFR) during and after STEMI: a single-centre, methodological study comparing estimated and measured GFR.

Venetsanos D, Alfredsson J, Segelmark M, Swahn E, Lawesson SS.

BMJ Open. 2015 Sep 23;5(9):e007835. doi: 10.1136/bmjopen-2015-007835.

26.

Trends in dialysis modality choice and related patient survival in the ERA-EDTA Registry over a 20-year period.

van de Luijtgaarden MW, Jager KJ, Segelmark M, Pascual J, Collart F, Hemke AC, Remón C, Metcalfe W, Miguel A, Kramar R, Aasarød K, Abu Hanna A, Krediet RT, Schön S, Ravani P, Caskey FJ, Couchoud C, Palsson R, Wanner C, Finne P, Noordzij M.

Nephrol Dial Transplant. 2016 Jan;31(1):120-8. doi: 10.1093/ndt/gfv295. Epub 2015 Aug 26.

PMID:
26311215
27.

BPI-ANCA Provides Additional Clinical Information to Anti-Pseudomonas Serology: Results from a Cohort of 117 Swedish Cystic Fibrosis Patients.

Lindberg U, Carlsson M, Hellmark T, Segelmark M.

J Immunol Res. 2015;2015:947934. doi: 10.1155/2015/947934. Epub 2015 Jul 26.

28.

Increased levels of neutrophil extracellular trap remnants in the circulation of patients with small vessel vasculitis, but an inverse correlation to anti-neutrophil cytoplasmic antibodies during remission.

Söderberg D, Kurz T, Motamedi A, Hellmark T, Eriksson P, Segelmark M.

Rheumatology (Oxford). 2015 Nov;54(11):2085-94. doi: 10.1093/rheumatology/kev217. Epub 2015 Jul 12.

29.

Outcome and treatment of elderly patients with ANCA-associated vasculitis.

Weiner M, Goh SM, Mohammad AJ, Hruskova Z, Tanna A, Bruchfeld A, Selga D, Chocova Z, Westman K, Eriksson P, Pusey CD, Tesar V, Salama AD, Segelmark M.

Clin J Am Soc Nephrol. 2015 Jul 7;10(7):1128-35. doi: 10.2215/CJN.00480115. Epub 2015 Jun 22.

30.

[The council for new therapies should immediately revoke their decision on eculizumab].

Karpman D, Fehrman-Ekholm I, Bárány P, Békássy Z, Brandström P, Bruchfeld A, Celsi G, Chromek M, Clyne N, Fellström B, Hansson S, Haraldsson B, Nevéus T, Rippe B, Sartz L, Segelmark M, Stegmayr B, Stenvinkel P, Westman K.

Lakartidningen. 2015 Jun 11;112. pii: DI7D. Swedish. No abstract available.

31.

[The council for new therapies position on eculizumab is unacceptable].

Karpman D, Fehrman-Ekholm I, Bárány P, Békássy Z, Brandström P, Bruchfeld A, Celsi G, Chromek M, Clyne N, Fellström B, Hansson S, Haraldsson B, Nevéus T, Rippe B, Sartz L, Segelmark M, Stegmayr B, Stenvinkel P, Tufveson G, Westman K.

Lakartidningen. 2015 Jun 9;112. pii: DI3F. Swedish. No abstract available.

32.

Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab.

Shah S, Hruskova Z, Segelmark M, Morgan MD, Hogan J, Lee SK, Dale J, Harper L, Tesar V, Jayne DR, Geetha D.

Am J Nephrol. 2015;41(4-5):296-301. doi: 10.1159/000431336. Epub 2015 Jun 2.

33.

Circulating microRNA expression pattern separates patients with anti-neutrophil cytoplasmic antibody associated vasculitis from healthy controls.

Skoglund C, Carlsen AL, Weiner M, Kurz T, Hellmark T, Eriksson P, Heegaard NH, Segelmark M.

Clin Exp Rheumatol. 2015 Mar-Apr;33(2 Suppl 89):S-64-71. Epub 2015 May 26.

PMID:
26016752
34.

Rituximab for treatment of severe renal disease in ANCA associated vasculitis.

Geetha D, Hruskova Z, Segelmark M, Hogan J, Morgan MD, Cavero T, Eriksson P, Seo P, Manno RL, Dale J, Harper L, Tesar V, Jayne DR.

J Nephrol. 2016 Apr;29(2):195-201. doi: 10.1007/s40620-015-0208-y. Epub 2015 May 19.

PMID:
25986390
35.

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.

Jones RB, Furuta S, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh M, Westman K, Jayne DR; European Vasculitis Society (EUVAS).

Ann Rheum Dis. 2015 Jun;74(6):1178-82. doi: 10.1136/annrheumdis-2014-206404. Epub 2015 Mar 4.

PMID:
25739829
36.

Incidence and disease severity of anti-neutrophil cytoplasmic antibody-associated nephritis are higher than in lupus nephritis in Sweden.

Mohammad AJ, Weiner M, Sjöwall C, Johansson ME, Bengtsson AA, Ståhl-Hallengren C, Nived O, Eriksson P, Sturfelt G, Segelmark M.

Nephrol Dial Transplant. 2015 Apr;30 Suppl 1:i23-30. doi: 10.1093/ndt/gfu396. Epub 2014 Dec 23.

PMID:
25540097
37.

[Phosphate additives in food a potential public health risk. High phosphate levels can lead to cardiovascular disease].

Stenvinkel P, Irving GF, Wegener S, Eyre S, Rippe B, Segelmark M, Barany P, Samuelsson O.

Lakartidningen. 2014 Jul 2-15;111(27-28):1176-9. Review. Swedish. No abstract available.

38.

The neutrophil serine protease PR3 induces shape change of platelets via the Rho/Rho kinase and Ca(2+) signaling pathways.

Peng X, Ramström S, Kurz T, Grenegård M, Segelmark M.

Thromb Res. 2014 Aug;134(2):418-25. doi: 10.1016/j.thromres.2014.06.001. Epub 2014 Jun 11.

39.

In Reply to 'IgG4-Restricted Anti-Glomerular Basement Membrane Autoantibodies Targeting Quaternary Epitopes of Native α345(IV) Collagen'.

Ohlsson S, Segelmark M.

Am J Kidney Dis. 2014 Jul;64(1):157. doi: 10.1053/j.ajkd.2014.04.023. No abstract available.

40.
41.

Neutrophils from vasculitis patients exhibit an increased propensity for activation by anti-neutrophil cytoplasmic antibodies.

Ohlsson SM, Ohlsson S, Söderberg D, Gunnarsson L, Pettersson Å, Segelmark M, Hellmark T.

Clin Exp Immunol. 2014 Jun;176(3):363-72. doi: 10.1111/cei.12301.

42.

Diagnosis and classification of Goodpasture's disease (anti-GBM).

Hellmark T, Segelmark M.

J Autoimmun. 2014 Feb-Mar;48-49:108-12. doi: 10.1016/j.jaut.2014.01.024. Epub 2014 Jan 21. Review.

PMID:
24456936
43.

A candidate gene approach to ANCA-associated vasculitis reveals links to the C3 and CTLA-4 genes but not to the IL1-Ra and Fcγ-RIIa genes.

Persson U, Gullstrand B, Pettersson A, Sturfelt G, Truedsson L, Segelmark M.

Kidney Blood Press Res. 2013;37(6):641-8. doi: 10.1159/000355744. Epub 2013 Dec 14.

44.

Primary systemic vasculitis with severe α1-antitrypsin deficiency revisited.

Mohammad A, Segelmark M.

Scand J Rheumatol. 2014;43(3):242-5. doi: 10.3109/03009742.2013.846405. Epub 2013 Dec 9.

PMID:
24313382
45.

A myelopoiesis gene signature during remission in anti-neutrophil cytoplasm antibody-associated vasculitis does not predict relapses but seems to reflect ongoing prednisolone therapy.

Kurz T, Weiner M, Skoglund C, Basnet S, Eriksson P, Segelmark M.

Clin Exp Immunol. 2014 Feb;175(2):215-26. doi: 10.1111/cei.12236.

46.

Circulating anti-glomerular basement membrane antibodies with predominance of subclass IgG4 and false-negative immunoassay test results in anti-glomerular basement membrane disease.

Ohlsson S, Herlitz H, Lundberg S, Selga D, Mölne J, Wieslander J, Segelmark M.

Am J Kidney Dis. 2014 Feb;63(2):289-93. doi: 10.1053/j.ajkd.2013.08.032. Epub 2013 Nov 1.

PMID:
24189476
47.

Replacement of acetate with citrate in dialysis fluid: a randomized clinical trial of short term safety and fluid biocompatibility.

Grundström G, Christensson A, Alquist M, Nilsson LG, Segelmark M.

BMC Nephrol. 2013 Oct 9;14:216. doi: 10.1186/1471-2369-14-216.

48.

Excellent long time survival for Swedish patients starting home-hemodialysis with and without subsequent renal transplantations.

Rydell H, Krützen L, Simonsen O, Clyne N, Segelmark M.

Hemodial Int. 2013 Oct;17(4):523-31. doi: 10.1111/hdi.12046. Epub 2013 Apr 11.

PMID:
23577698
49.

L23. Renal transplantation in ANCA-associated vasculitis.

Segelmark M.

Presse Med. 2013 Apr;42(4 Pt 2):568-71. doi: 10.1016/j.lpm.2013.01.023. Epub 2013 Mar 1. Review. No abstract available.

PMID:
23453993
50.

Circulating microRNA expression profiles associated with systemic lupus erythematosus.

Carlsen AL, Schetter AJ, Nielsen CT, Lood C, Knudsen S, Voss A, Harris CC, Hellmark T, Segelmark M, Jacobsen S, Bengtsson AA, Heegaard NH.

Arthritis Rheum. 2013 May;65(5):1324-34. doi: 10.1002/art.37890.

Supplemental Content

Loading ...
Support Center